Top Markets
Coin of the day
Ember Therapeutics, Inc. Ember Therapeutics, Inc.

Ember Therapeutics, Inc.

EMBT
Rangering i aksjer #42686
Ember Therapeutics, Inc. operates as a biopharmaceutical company currently in... Ember Therapeutics, Inc. operates as a biopharmaceutical company currently in its clinical development phase. Its core mission involves exploring the therapeutic applications of bone morphogenetic protein-7 (BMP-7) to engineer regenerative treatments. These innovative therapies are designed to alter the course of osteoarthritis, reverse insulin resistance, and inhibit or undo organ fibrosis in diseases such as chronic kidney disease and Alport's syndrome, alongside metabolic conditions like obesity and type 2 diabetes. Among its leading BMP-7-based drug candidates, MT-006 has successfully completed a Phase 2a clinical trial focused on osteoarthritis. Furthermore, MT-007, aimed at CKD and Alport syndrome; MT-008, specifically for Alport syndrome; and MT-009, targeting metabolic disease, have all concluded their preclinical trial phases. The company also maintains a substantial intellectual property portfolio, encompassing approximately 450 patents related to BMP-7, its associated protein families, various derivatives, novel delivery systems, specialized formulations, supporting clinical data, and materials produced under current good manufacturing practices. Ember Therapeutics, Inc. was established in 2010 and is headquartered in New York, New York.
Aksjekurs
$0.0001
Sist synkronisert: 2026-02-06
Markedsverdi
$398.00
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
US
Handel Ember Therapeutics, Inc. (EMBT)

Kategori

EPS for Ember Therapeutics, Inc. (EMBT)
EPS per 2026 TTM: 0
Ifølge de siste økonomiske rapportene og aksjekursen til Ember Therapeutics, Inc. er selskapets nåværende EPS (TTM) 0. Ved slutten av 2026 hadde selskapet en EPS på 0, lik EPS-en i 2026 som var 0.
EPS-historikk for Ember Therapeutics, Inc. fra 2026 til 2026
EPS ved slutten av hvert år
År EPS Endre
Ikke nok data for de angitte datoene.
EPS for lignende selskaper eller konkurrenter